Quadrant Capital Group LLC Syndax Pharmaceuticals Inc Transaction History
Quadrant Capital Group LLC
- $2.65 Billion
- Q1 2025
A detailed history of Quadrant Capital Group LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 194 shares of SNDX stock, worth $1,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
194
Previous 1,018
80.94%
Holding current value
$1,839
Previous $13,000
84.62%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$80.8 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$75 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$46.2 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$39.9 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$38 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $536M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...